CSBR
What one share of Champions Oncology holds
Biological Products, (No Diagnostic Substances)
We are a technology-enabled research organization engaged in creating technology solutions to be utilized in drug discovery and development. Our research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms.
Champions Oncology’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-07-31; the balance sheet is as of 2026-07-31.
| Sales | $4.38 |
|---|---|
| Profit | −$0.08 |
| Capex (buildings and equipment) | $0.04 |
| Free cash flow | −$0.44 |
| Cash and investments | $0.31 |
| Book value | $0.28 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | — | −$0.64 | $0.07 | −$0.34 | — | — |
| 2018 | $1.84 | −$0.13 | $0.11 | −$0.22 | — | — |
| 2019 | $0.21 | $0.01 | $0.06 | $0.07 | — | $0.18 |
| 2020 | $2.71 | −$0.18 | $0.19 | $0.06 | — | $0.40 |
| 2021 | $2.82 | $0.02 | $0.23 | −$0.34 | — | $0.55 |
| 2022 | $3.47 | $0.04 | $0.17 | $0.29 | — | $0.67 |
| 2023 | $3.98 | −$0.39 | $0.21 | $0.08 | — | $0.34 |
| 2024 | $3.70 | −$0.54 | $0.06 | −$0.51 | — | −$0.14 |
| 2025 | $3.99 | $0.33 | $0.03 | $0.49 | — | $0.27 |
| 2026 | $4.30 | −$0.08 | $0.04 | −$0.36 | — | $0.28 |